Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4484070 | 0.91 | CYP1A2 (0.52) | CYP1A2ALOX5SMN1; SMN2CYP2D6TSHR | |
| SCHEMBL9680733 | 0.85 | PTGS2 (0.52) | CYP1A2ALOX5SMN1; SMN2CYP2D6TSHR | |
| SCHEMBL421564 | 0.80 | PTGS2 (0.61) | CYP1A2ALOX5SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL5149430 | 0.80 | PTGS2 (0.61) | CYP1A2ALOX5SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL12280124 | 0.80 | CYP1A2 (0.55) | CYP1A2ALOX5SMN1; SMN2CYP2D6TSHR | |
| SCHEMBL24519245 | 0.80 | ALOX5 (0.46) | ALOX5SMN1; SMN2TSHRALDH1A1LMNA | |
| SCHEMBL3860971 | 0.80 | PTGS2 (0.61) | CYP1A2ALOX5SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL2291864 | 0.78 | CYP1A2 (0.48) | CYP1A2ALOX5SMN1; SMN2CYP2D6TSHR | |
| SCHEMBL3875094 | 0.78 | EPHX1 (0.58) | CYP1A2ALOX5SMN1; SMN2CYP2D6TSHR | |
| SCHEMBL4493827 | 0.78 | EPHX1 (0.58) | CYP1A2ALOX5SMN1; SMN2CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2024-07-18 | — | — | US | disclosed |
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | FAP, FIBP, FGFR1 | CYP1A2 4662/4885ALOX5 2753/4885SMN1; SMN2 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.